--- title: Opioids: FDA Wants Opana Pulled From the Market description: The FDA wants Opana ER pulled from the market, citing the nation's opioid epidemic and the drug's potential for addiction and abuse canonical: https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/ author: Amanda MacMillan article:opinion: false article:content_tier: free article:published_time: 2017-06-09T15:44:19.000Z article:modified_time: 2026-02-23T05:21:33.265Z article:section: Health og:title: The FDA Wants This Opioid Drug Pulled From the Market og:description: It's first time the FDA has attempted to halt a medication over abuse concerns og:url: https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltde093bcdab65f2d0/6988d9b9bc6cfc69913e2a3c/time-logo.jpg?branch=production og:image:width: 1200 og:image:height: 675 og:image:alt: TIME og:type: article twitter:card: summary_large_image twitter:title: The FDA Wants This Opioid Drug Pulled From the Market twitter:description: It's first time the FDA has attempted to halt a medication over abuse concerns twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltde093bcdab65f2d0/6988d9b9bc6cfc69913e2a3c/time-logo.jpg?branch=production --- # The FDA Wants This Opioid Drug Pulled From the Market > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=4ace9be6-13bb-4add-82ea-2cb1a2329345&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=4ace9be6-13bb-4add-82ea-2cb1a2329345&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=4ace9be6-13bb-4add-82ea-2cb1a2329345&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=4ace9be6-13bb-4add-82ea-2cb1a2329345&cr=time-nl-network-2026q3-v1) by [Amanda MacMillan](https://time.com/author/amanda-macmillan/) ## Amanda MacMillan Jun 9, 2017 3:44 PM UTC by [Amanda MacMillan](https://time.com/author/amanda-macmillan/) ## Amanda MacMillan Jun 9, 2017 3:44 PM UTC The U.S. Food and Drug Administration (FDA) requested on Thursday that the drug Opana ER be [pulled from the market](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm) — the first time the agency has taken steps to remove a currently prescribed opioid pain medication from the market because of its potential for abuse. The request, at this time, is voluntary. Opana manufacturer Endo Pharmaceuticals said in a statement Thursday that the company “is [reviewing the request](http://www.prnewswire.com/news-releases/endo-response-to-june-8-2017-fda-meeting-related-to-opana-er-300471441.html) and is evaluating the full range of potential options as we determine the appropriate path forward.” In an FDA statement announcing the request, Dr. Scott Gottlieb, commissioner of food and drugs, cited the country’s ongoing opioid epidemic as a reason for the agency’s actions. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits,” he said, “not only for its intended patient population but also in regard to its potential for misuse and abuse.” Opana ER (extended-release) was approved in 2006 for the management of moderate-to-severe pain when around-the-clock relief is needed. Because of the increased risks of addiction and overdose with extended-release opioids, doctors are instructed to prescribe Opana ER only to patients for whom alternative treatment options are ineffective, not tolerated or otherwise inadequate. In 2012, Opana ER was reformulated with the intention of making the tablets more resistant to manipulation for abuse by snorting or injecting. But the FDA determined that there wasn’t enough data to show the reformulation could meaningfully reduce abuse — and it declined Endo’s request to tout any abuse-deterrent properties on the label. Now, the FDA says it has concerns that the benefits of the drug no longer outweigh its risks. Following the [product’s reformulation](http://time.com/3912539/fda-opana/), the agency says, data has shown a “significant shift in the route of abuse of Opana ER from nasal to injection.” Injecting the drug has been associated with a serious [outbreak of HIV](http://time.com/3761476/indiana-hiv-outbreak-epidemic-mike-pence/) and [hepatitis C](http://time.com/4775698/hepatitis-c-diagnosis/), as well as cases of a serious blood disorder. “When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, in the FDA’s statement. “This action will protect the public from further potential for misuse and abuse of this product.” If Endo chooses not to remove Opana ER from the market, the FDA intends to formally withdraw approval. The agency says it will also continue to examine the risks and benefits of all approved opioid pain medicines, “and will take further actions as appropriate as a part of our response to this public health crisis.” In its own statement, Endo acknowledged that the misuse and abuse of opioids have greatly increased in the United States. But it also stresses that the FDA’s request “does not indicate uncertainty with the product’s safety or efficacy when taken as prescribed.” It also notes that, while an FDA advisory committee voted 18 to 8 that Opana ER’s benefits no longer outweigh its risks, more than half of the committee members expressed their preference that the drug remain on the market with new regulatory restrictions. Although official government data for 2016 has not yet been released, preliminary data compiled by the _New York Times_ shows that U.S. drug overdose deaths last year most [likely exceeded 59,000 ](https://www.nytimes.com/interactive/2017/06/05/upshot/opioid-epidemic-drug-overdose-deaths-are-rising-faster-than-ever.html)— the largest annual jump ever recorded. Overdosing — on opioids as well as illicitly manufactured drugs — is now the leading cause of death among Americans under age 50, the newspaper reported this week. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/"},"headline":"The FDA Wants This Opioid Drug Pulled From the Market","datePublished":"2017-06-09T15:44:19.000Z","dateModified":"2026-02-23T05:21:33.265Z","description":"This is the first time the FDA has attempted to remove a medication from sale for concerns over potential abuse.","url":"https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/","keywords":["health","onetime"],"thumbnailUrl":"","author":[{"@type":"Person","name":"Amanda MacMillan","jobTitle":null,"url":"https://time.com/author/amanda-macmillan/"}],"articleSection":"Health","image":[],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/health/","name":"health"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/4812756/fda-wants-opioid-drug-opana-pulled/","name":"The FDA Wants This Opioid Drug Pulled From the Market"}}]}] ```